Pharmafile Logo

severe hypertriglyceridemia

- PMLiVE

FDA approves COVID-19 treatment for those under the age of 12

Veklury is currently the only COVID-19 treatment approved for this age group

- PMLiVE

AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19

The drug decreases the risk of developing symptomatic COVID-19 by 77% among high-risk populations

- PMLiVE

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

The site in the US will produce CAR T-cell therapies for patients with blood cancers

- PMLiVE

Enhertu to provide patients with vital targeted therapy option

Therapy receives FDA priority review as patients with HER2-mutant metastatic non-small cell lung cancer seek alternative treatment

- PMLiVE

FDA delays Merck’s pneumococcal vaccine Vaxneuvance

It is predicted that the vaccine could make over $1bn in peak sales

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

AstraZeneca to present new oncology data at AACR

The American Association for Cancer Research Annual Meeting takes place in New Orleans from 8-13 April 2022

- PMLiVE

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

Pfizer receives Breakthrough Therapy Designation from FDA for RSV vaccine candidate

There are currently no preventative, therapeutic or vaccine options for older adults diagnosed with RSV

- PMLiVE

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma

The new, first-in-class fixed-dose dual immunotherapy combination treatment is administered as a single intravenous infusion

- PMLiVE

Merck’s Keytruda receives FDA approval for advanced endometrial cancer

The approval was based on new data from the KEYNOTE-158 trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links